Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase III open-label extension study of jaktinib in active ankylosing spondylitis
CTR20231389Phase 3Completed
- Sponsor
- Zelgen
- Start
- Nov 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of jaktinib in ankylosing spondylitis (AS), sponsored by Zelgen. Started Nov 2023; status: completed.
02
Drugs
jaktinib
03
Conditions
ankylosing spondylitis (AS)
Beyond the preview
Go deeper on CTR20231389.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20231389.